-
公开(公告)号:US20100227903A1
公开(公告)日:2010-09-09
申请号:US12223272
申请日:2007-02-09
IPC分类号: A61K31/421 , A61P9/00
CPC分类号: A61K9/1652 , A61K9/1635 , A61K9/1694 , A61K9/2027 , A61K9/2054
摘要: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
摘要翻译: 药物组合物包含(a)CETP抑制化合物或其药学上可接受的盐; (b)浓缩增强聚合物,和(c)任选的一种或多种表面活性剂; 其中所述化合物具有如下式I所示的结构。 该组合物提高HDL-胆固醇并降低LDL-胆固醇。
-
公开(公告)号:US08030359B2
公开(公告)日:2011-10-04
申请号:US12223272
申请日:2007-02-09
CPC分类号: A61K9/1652 , A61K9/1635 , A61K9/1694 , A61K9/2027 , A61K9/2054
摘要: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
摘要翻译: 药物组合物包含(a)CETP抑制化合物或其药学上可接受的盐; (b)浓缩增强聚合物,和(c)任选的一种或多种表面活性剂; 其中所述化合物具有如下式I所示的结构。 该组合物提高HDL-胆固醇并降低LDL-胆固醇。
-
公开(公告)号:US20160287568A1
公开(公告)日:2016-10-06
申请号:US15038373
申请日:2014-11-19
申请人: John M. BAUMANN , Michael LOWINGER , Aditya S. TATAVARTI , Patrick Jules MARSAC , Kristin J. M. PLOEGER , Corey J. BLOOM , Katherine Anne BROOKHART , MERCK SHARP & DOHME CORP.
发明人: Michael Lowinger , Aditya S. Tatavarti , Patrick Jules Marsac , Kristin J.M. Ploeger , John M. Baumann , Corey J. Bloom , Katherine Anne Brookhart
IPC分类号: A61K31/4439 , A61K9/16
CPC分类号: A61K31/4439 , A61K9/1652 , A61K9/1682 , A61K9/4808
摘要: The invention encompasses a composition comprising the reverse transcriptase (“RT”) inhibitor 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile sufficiently mixed in a concentration enhancing polymer, and processes for making the same. The composition and processes of the present invention significantly improve the bioavailability of the aforementioned RT inhibitor, while maintaining physical stability.
摘要翻译: 本发明包括含有逆转录酶(“RT”)抑制剂3-氯-5 - ({1 - [(4-甲基-5-氧代-4,5-二氢-1H-1,2,4-三唑) -3-基)甲基] -2-氧代-4-(三氟甲基)-1,2-二氢吡啶-3-基}氧基)苄腈及其制备方法。 本发明的组合物和方法在保持物理稳定性的同时显着提高了上述RT抑制剂的生物利用度。
-
-